10-K Filing

ENVERIC BIOSCIENCES, INC. CIK: 890821 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0001493152-21-007757`
Period End Date	20201231
Filing Date	20210401
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	amrh-20201231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 53 Income Statement 24 Cash Flow Statement 62 Stockholders Equity 27

Balance Sheet 53 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	20.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	20.00M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	262,500.00	shares	Point-in-time
Cash	`Cash`	$1.58M	USD	Point-in-time
Cash	`Cash`	$43.71K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	3.28M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$65.08K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	262,500.00	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$700.71K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	3.28M	shares	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.28M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Total current assets	`AssetsCurrent`	$108.79K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Intangible assets	`IntangibleAssetsNetExcludingGoodwill`	$1.82M	USD	Point-in-time
Intangible assets	`IntangibleAssetsNetExcludingGoodwill`	-	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Total assets	`Assets`	$4.10M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.31M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	10.10M	shares	Point-in-time
Total assets	`Assets`	$108.79K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.31M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	10.10M	shares	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent`	$1.16M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent`	$681.25K	USD	Point-in-time
Advance from related party	`DueToRelatedPartiesCurrent`	-	USD	Point-in-time
Advance from related party	`DueToRelatedPartiesCurrent`	$22.41K	USD	Point-in-time
Notes payable	`NotesPayableExcludingConvertibleNotespayable`	-	USD	Point-in-time
Notes payable	`NotesPayableExcludingConvertibleNotespayable`	$446.42K	USD	Point-in-time
Convertible notes payable	`ConvertibleNotesPayableCurrent`	$293.92K	USD	Point-in-time
Convertible notes payable	`ConvertibleNotesPayableCurrent`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$1.92M	USD	Point-in-time
Total liabilities	`Liabilities`	$681.25K	USD	Point-in-time
Commitments (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred Stock, $0.01 par value, 20,000,000 shares authorized, 3,275,407 and 262,500 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	`PreferredStockValue`	$2.62K	USD	Point-in-time
Preferred Stock, $0.01 par value, 20,000,000 shares authorized, 3,275,407 and 262,500 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	`PreferredStockValue`	$32.75K	USD	Point-in-time
Common stock, $0.01 par value, 100,000,000 shares authorized, 10,095,109 and 5,311,414 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	`CommonStockValue`	$53.11K	USD	Point-in-time
Common stock, $0.01 par value, 100,000,000 shares authorized, 10,095,109 and 5,311,414 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	`CommonStockValue`	$100.95K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.04M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$15.22M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-4.89M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-11.76M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-11.62K	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-181.28K	USD	Point-in-time
Total shareholders' equity (deficit)	`StockholdersEquity`	$-1.81M	USD	Point-in-time
Total shareholders' equity (deficit)	`StockholdersEquity`	$-65.45K	USD	Point-in-time
Total shareholders' equity (deficit)	`StockholdersEquity`	$3.42M	USD	Point-in-time
Total liabilities and shareholders' equity (deficit)	`LiabilitiesAndStockholdersEquity`	$108.79K	USD	Point-in-time
Total liabilities and shareholders' equity (deficit)	`LiabilitiesAndStockholdersEquity`	$4.10M	USD	Point-in-time

Income Statement 24 line items

Line Item	Tag	Value	Unit	Period
General and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$5.44M	USD	Annual
General and administrative expenses	`SellingGeneralAndAdministrativeExpense`	$2.30M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$174.08K	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	-	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-2.30M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-5.62M	USD	Annual
Extinguishment of note payable	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Extinguishment of note payable	`GainsLossesOnExtinguishmentOfDebt`	$32.32K	USD	Annual
Interest expense	`InterestExpense`	$81.82K	USD	Annual
Interest expense	`InterestExpense`	$445.25K	USD	Annual
Inducement expense	`InducementExpense`	$-802.11K	USD	Annual
Inducement expense	`InducementExpense`	-	USD	Annual
Total other expense	`NonoperatingIncomeExpense`	$1.25M	USD	Annual
Total other expense	`NonoperatingIncomeExpense`	$114.14K	USD	Annual
Net loss	`NetIncomeLoss`	$-2.41M	USD	Annual
Net loss	`NetIncomeLoss`	$-6.86M	USD	Annual
Foreign exchange loss	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-169.66K	USD	Annual
Foreign exchange loss	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-6.67K	USD	Annual
Comprehensive loss	`OtherComprehensiveIncomeLossTax`	$-7.03M	USD	Annual
Comprehensive loss	`OtherComprehensiveIncomeLossTax`	$-2.42M	USD	Annual
Net loss per share - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.19	USD	Annual
Net loss per share - basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.46	USD	Annual
Weighted average shares outstanding, basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	5.29M	shares	Annual
Weighted average shares outstanding, basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	5.75M	shares	Annual

Cash Flow Statement 62 line items

Line Item	Tag	Value	Unit	Period
Net loss	`OtherComprehensiveIncomeLossTaxPortionAttributableToParent1`	$-6.86M	USD	Annual
Net loss	`OtherComprehensiveIncomeLossTaxPortionAttributableToParent1`	$-2.41M	USD	Annual
Extinguishment of note payable	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Extinguishment of note payable	`GainsLossesOnExtinguishmentOfDebt`	$32.32K	USD	Annual
Accrued interest	`AccruedInterest`	$13.68K	USD	Annual
Accrued interest	`AccruedInterest`	$156.62K	USD	Annual
Amortization of debt discount	`AmortizationOfFinancingCostsAndDiscounts`	$288.63K	USD	Annual
Amortization of debt discount	`AmortizationOfFinancingCostsAndDiscounts`	$68.45K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$624.05K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$1.98M	USD	Annual
Inducement expense	`GainsLossesOnInducementExpense`	-	USD	Annual
Inducement expense	`GainsLossesOnInducementExpense`	$-802.11K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$120.87K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	-	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-104.34K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$636.50K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$919.97K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$267.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-647.86K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.89M	USD	Annual
Purchase of Tikkun Pharma license agreement	`PaymentsForPurchaseOfLicenseAgreement`	$44.14K	USD	Annual
Purchase of Tikkun Pharma license agreement	`PaymentsForPurchaseOfLicenseAgreement`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-44.14K	USD	Annual
Proceeds from convertible notes payable	`ProceedsFromConvertibleDebt`	$50.00K	USD	Annual
Proceeds from convertible notes payable	`ProceedsFromConvertibleDebt`	$300.00K	USD	Annual
Proceeds from note payable, net of offering costs	`ProceedsFromNotesPayable`	$1.81M	USD	Annual
Proceeds from note payable, net of offering costs	`ProceedsFromNotesPayable`	$238.00K	USD	Annual
Advances from related party	`ProceedsFromRelatedPartyDebt`	-	USD	Annual
Advances from related party	`ProceedsFromRelatedPartyDebt`	$22.00K	USD	Annual
Advances from related party	`ProceedsFromRelatedPartyDebt`	$22.00K	USD	Point-in-time
Offering and Reverse Merger proceeds	`ProceedsFromOfferingAndReverseMergerProceeds`	-	USD	Annual
Offering and Reverse Merger proceeds	`ProceedsFromOfferingAndReverseMergerProceeds`	$3.37M	USD	Annual
September 2020 private placement	`ProceedsFromIssuanceOfPrivatePlacement`	$227.50K	USD	Annual
December 2020 private placement	`ProceedsFromIssuanceOfPrivatePlacementOne`	$260.50K	USD	Annual
Repayment of note payable	`RepaymentsOfNotesPayable`	$191.64K	USD	Annual
Repayment of note payable	`RepaymentsOfNotesPayable`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.53M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$560.00K	USD	Annual
Effect of foreign exchange rate on cash	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-63.60K	USD	Annual
Effect of foreign exchange rate on cash	`EffectOfExchangeRateOnCashAndCashEquivalents`	$17.90K	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.53M	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-69.96K	USD	Annual
Cash - beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$113.67K	USD	Point-in-time
Cash - beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$43.71K	USD	Point-in-time
Cash - beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.58M	USD	Point-in-time
Cash - end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$113.67K	USD	Point-in-time
Cash - end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$43.71K	USD	Point-in-time
Cash - end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.58M	USD	Point-in-time
Beneficial conversion feature issued with note payable	`DebtInstrumentConvertibleBeneficialConversionFeature`	$17.85K	USD	Annual
Warrants issued in conjunction with notes payable	`WarrantsIssuedInConjunctionWithNotesPayable`	$24.88K	USD	Annual
Warrants issued in conjunction with notes payable	`WarrantsIssuedInConjunctionWithNotesPayable`	$32.15K	USD	Annual
Common stock issued for accounts payable	`StockIssued1`	$756.52K	USD	Annual
Common stock issued for accounts payable	`StockIssued1`	-	USD	Annual
Common stock issued in conjunction with note payable modification	`CommonStockIssuedInConjunctionWithNotePayableModification`	$22.27K	USD	Annual
Common stock issued in conjunction with note payable modification	`CommonStockIssuedInConjunctionWithNotePayableModification`	$101.71K	USD	Annual
Notes payable issued to consultant for prepaid services	`NotesIssued1`	$150.00K	USD	Annual
Notes payable issued to consultant for prepaid services	`NotesIssued1`	-	USD	Annual
Conversion of related party advances and notes payable into common stock	`ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock`	$679.57K	USD	Annual
Conversion of related party advances and notes payable into common stock	`ConversionOfRelatedPartyAdvancesAndNotesPayableIntoCommonStock`	-	USD	Annual
Common stock issued for skincare license	`CommonStockIssuedForSkincareLicense`	$1.90M	USD	Annual
Common stock issued for skincare license	`CommonStockIssuedForSkincareLicense`	-	USD	Annual

Stockholders Equity 27 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$-1.81M	USD	Point-in-time
Balance	`StockholdersEquity`	$-65.45K	USD	Point-in-time
Balance	`StockholdersEquity`	$3.42M	USD	Point-in-time
September 2020 private placement	`StockIssuedDuringPeriodValueIssuedPrivatePlacement`	$227.50K	USD	Annual
December 2020 private placement	`StockIssuedDuringPeriodValueIssuedPrivatePlacementOne`	$260.50K	USD	Annual
Acquisition of Tikkun Pharma IP	`StockIssuedDuringPeriodValueAcquisitions`	$1.90M	USD	Annual
Alpha financing and conversion of Alpha Note, including Palladium shares	`FinancingAndConversionOfNoteIncludingPalladiumShares`	$4.82M	USD	Annual
Exchange of warrants for common shares	`StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonShares`	$841.88K	USD	Annual
Conversion of related party advance and notes payable	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$679.57K	USD	Annual
Common stock issued for accounts payable	`StockIssuedDuringPeriodValueCommonStockIssuedForAccountsPayable`	$756.52K	USD	Annual
Common stock issued for services	`StockIssuedDuringPeriodValueIssuedForServices`	$88.47K	USD	Annual
Warrants issued in conjunction with notes payable	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$32.15K	USD	Annual
Warrants issued in conjunction with notes payable	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$24.88K	USD	Annual
Beneficial conversion feature issued with note payable	`AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature`	$17.85K	USD	Annual
Common stock issued in conjunction with note payable modification	`AdjustmentsToAdditionalPaidInCapitalCommonStockIssuedInConjunctionWithNotePayableModification`	$101.71K	USD	Annual
Stock option expense	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition`	$1.98M	USD	Annual
Conversion of Series B preferred stock to common stock	`StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock`	-	USD	Annual
Merger with Ameri Holdings, Inc.	`StockIssuedDuringPeriodValueAcquisitionsOne`	$650.00K	USD	Annual
Shares issued in connection with note extension	`StockIssuedDuringPeriodValueOther`	$22.27K	USD	Annual
Stock based compensation - stock options	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$535.59K	USD	Annual
Foreign exchange loss	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-169.66K	USD	Annual
Foreign exchange loss	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-6.67K	USD	Annual
Net loss	`NetIncomeLoss`	$-2.41M	USD	Annual
Net loss	`NetIncomeLoss`	$-6.86M	USD	Annual
Balance	`StockholdersEquity`	$-1.81M	USD	Point-in-time
Balance	`StockholdersEquity`	$-65.45K	USD	Point-in-time
Balance	`StockholdersEquity`	$3.42M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.